Lupin expects to maintain US sales at around $1 billion over the next two years, supported by a steady stream of new product launches. The company has several launches lined up across injectables, ...

The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), for use in cancer patients at risk of infection due to chemotherapy. Filkri is indicated for patients receiving ...

Analysts have tweaked share price targets and future outlook after some of these companies announced their December quarter results.

Lupin has inked an agreement with Valorum for biosimilar Armlupeg. Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving ...

Armlupeg, a biosimilar to Neulasta, is approved for reducing febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. Lupin's FDA-approved facility in India ...

The MarketWatch News Department was not involved in the creation of this content. -- JAMP Pharma Group launches PrPexegra(R), a biosimilar alternative to the reference product PrNeulasta(R) ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The price you pay for Udenyca may depend on factors such as the form you take, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Lupin has received approval from Health Canada for pegfilgrastim, a biosimilar to Amgen's Neulasta. This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech ...

Neulasta (pegfilgrastim) is a prescription drug used to prevent infection from certain cancer therapy and to treat radiation sickness. Neulasta’s cost may depend on factors such as your dosage and the ...

Damineh Morsali PH.D., Robert Schwartz Ph.D. Pegfilgrastim Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation ...

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) ...